Mitchell L. Shiffman

53.8k total citations · 12 hit papers
275 papers, 34.4k citations indexed

About

Mitchell L. Shiffman is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Mitchell L. Shiffman has authored 275 papers receiving a total of 34.4k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Hepatology, 219 papers in Epidemiology and 34 papers in Surgery. Recurrent topics in Mitchell L. Shiffman's work include Liver Disease Diagnosis and Treatment (196 papers), Hepatitis C virus research (193 papers) and Hepatitis B Virus Studies (119 papers). Mitchell L. Shiffman is often cited by papers focused on Liver Disease Diagnosis and Treatment (196 papers), Hepatitis C virus research (193 papers) and Hepatitis B Virus Studies (119 papers). Mitchell L. Shiffman collaborates with scholars based in United States, Germany and France. Mitchell L. Shiffman's co-authors include Janice K. Albrecht, Stuart C. Gordon, John G. McHutchison, Vinod K. Rustgi, Zachary Goodman, Arun J. Sanyal, Velimir A. Luketic, Richard K. Sterling, Robert Reindollar and K. Rajender Reddy and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Mitchell L. Shiffman

272 papers receiving 33.2k citations

Hit Papers

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatiti... 1998 2026 2007 2016 2002 2001 1998 2001 1998 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
    2002 5.1k citations Michael Fried, Mitchell L. Shiffman et al. New England Journal of Medicine profile →
  2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    2001 4.8k citations John G. McHutchison, Stuart C. Gordon et al. profile →
  3. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
    1998 2.8k citations John G. McHutchison, Stuart C. Gordon et al. New England Journal of Medicine profile →
  4. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
    2001 1.7k citations Arun J. Sanyal, Velimir A. Luketic et al. Gastroenterology profile →
  5. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C
    1998 1.1k citations Gary L. Davis, Rafael Esteban et al. New England Journal of Medicine profile →
  6. Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values
    2003 909 citations Velimir A. Luketic, Mitchell L. Shiffman et al. Hepatology profile →
  7. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    2009 889 citations John G. McHutchison, Eric Lawitz et al. New England Journal of Medicine profile →
  8. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
    2000 682 citations Mitchell L. Shiffman, Geoffrey Dusheiko et al. New England Journal of Medicine profile →
  9. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
    2014 646 citations Fred Poordad, Kris V. Kowdley et al. New England Journal of Medicine profile →
  10. A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
    2001 507 citations Karen L. Lindsay, Christian Trépo et al. Hepatology profile →
  11. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
    2019 255 citations Arun J. Sanyal, Stephen A. Harrison et al. Hepatology profile →
  12. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
    2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mitchell L. Shiffman United States 75 27.9k 27.7k 3.1k 2.8k 2.4k 275 34.4k
Antonio Craxı̀ Italy 73 20.4k 0.7× 20.5k 0.7× 2.5k 0.8× 1.9k 0.7× 1.8k 0.7× 519 27.1k
Zachary Goodman United States 88 31.0k 1.1× 33.3k 1.2× 4.5k 1.4× 3.4k 1.2× 2.9k 1.2× 299 42.1k
Thierry Poynard France 93 33.9k 1.2× 36.1k 1.3× 4.3k 1.4× 2.8k 1.0× 3.3k 1.3× 427 43.7k
Adrian M. Di Bisceglie United States 89 24.7k 0.9× 24.4k 0.9× 2.5k 0.8× 2.2k 0.8× 1.6k 0.6× 385 34.5k
Eugene R. Schiff United States 78 22.8k 0.8× 22.5k 0.8× 2.7k 0.9× 3.2k 1.2× 663 0.3× 372 28.9k
John G. McHutchison United States 95 37.2k 1.3× 33.6k 1.2× 1.7k 0.6× 4.7k 1.7× 871 0.4× 467 43.6k
Patrick Marcellin France 99 34.2k 1.2× 34.3k 1.2× 1.2k 0.4× 4.1k 1.5× 817 0.3× 635 38.8k
K. Rajender Reddy United States 88 28.3k 1.0× 24.9k 0.9× 5.3k 1.7× 3.9k 1.4× 610 0.3× 586 37.2k
Norah A. Terrault United States 82 19.7k 0.7× 21.2k 0.8× 3.9k 1.2× 2.0k 0.7× 2.1k 0.9× 457 26.8k
Raymond T. Chung United States 79 13.5k 0.5× 12.9k 0.5× 1.9k 0.6× 2.6k 0.9× 1.1k 0.4× 431 23.1k

Countries citing papers authored by Mitchell L. Shiffman

Since Specialization
Citations

This map shows the geographic impact of Mitchell L. Shiffman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell L. Shiffman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell L. Shiffman more than expected).

Fields of papers citing papers by Mitchell L. Shiffman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell L. Shiffman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell L. Shiffman. The network helps show where Mitchell L. Shiffman may publish in the future.

Co-authorship network of co-authors of Mitchell L. Shiffman

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell L. Shiffman. A scholar is included among the top collaborators of Mitchell L. Shiffman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell L. Shiffman. Mitchell L. Shiffman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shiffman, Mitchell L., K. Rajender Reddy, Michael D. Leise, et al.. (2024). Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT‐V Study. Alimentary Pharmacology & Therapeutics. 61(1). 75–87. 5 indexed citations
2.
Younossi, Zobair M., Maria Stepanova, Mazen Noureddin, et al.. (2021). Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatology Communications. 5(7). 1201–1211. 24 indexed citations
3.
Lok, Anna S., Mark Sulkowski, Jens Kort, et al.. (2019). Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 157(6). 1506–1517.e1. 34 indexed citations
4.
Shiffman, Mitchell L., B. Freilich, Raj Vuppalanchi, et al.. (2019). Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease. Publisher.
5.
Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, et al.. (2019). The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.. Hepatology. 3 indexed citations
6.
Foster, Graham R., Carmine Coppola, Moutaz Derbala, et al.. (2016). Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS ONE. 11(3). e0151703–e0151703. 15 indexed citations
7.
Sarrazin, Christoph, Francesco Castelli, Pietro Andreoné, et al.. (2016). HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Clinical and Experimental Gastroenterology. Volume 9. 351–363. 2 indexed citations
8.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2013). Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology. 146(2). 442–452.e1. 98 indexed citations
9.
Harrison, Stephen A., Mitchell L. Shiffman, И. Г. Бакулин, et al.. (2012). Intensified Peginterferon α-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. Journal of Clinical Gastroenterology. 47(3). 271–279. 3 indexed citations
10.
Shiffman, Mitchell L., Paul J. Pockros, John G. McHutchison, et al.. (2010). Clinical trial: the efficacy and safety of oral PF‐03491390, a pancaspase inhibitor – a randomized placebo‐controlled study in patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 31(9). 969–978. 89 indexed citations
11.
Shiffman, Mitchell L., Chihiro Morishima, Jules L. Dienstag, et al.. (2009). Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology. 137(6). 1986–1994. 30 indexed citations
12.
McHutchinson, John, Zachary Goodman, M. Rodríguez‐Torres, et al.. (2008). Double blind, randomized, placebo-controlled, multi-center,phase II dose ranging study to assess the antifibrotic activityof farglitazar in chronic hepatitis C infection.. Hepatology. 2 indexed citations
13.
Lindsay, Karen L., Chihiro Morishima, Elizabeth C. Wright, et al.. (2008). Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C. Clinical Gastroenterology and Hepatology. 6(2). 234–241. 22 indexed citations
14.
Lok, Anna S., James E. Everhart, Raymond T. Chung, et al.. (2007). Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology. 5(2). 245–254. 37 indexed citations
15.
Huang, Hongjin, Mitchell L. Shiffman, Scott L. Friedman, et al.. (2007). A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C†. Hepatology. 46(2). 297–306. 228 indexed citations
16.
Pockros, Paul J., Mitchell L. Shiffman, Eugene R. Schiff, et al.. (2004). Epoetin Alfa Improves Quality of Life in Anemic Hcv–Infected Patients Receiving Combination Therapy. Hepatology. 40(6). 1450–1458. 116 indexed citations
17.
Pockros, Paul J., Robert L. Carithers, Paul Desmond, et al.. (2004). Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial. The American Journal of Gastroenterology. 99(7). 1298–1305. 64 indexed citations
18.
Davis, Gary L., Rafael Esteban, Vinod K. Rustgi, et al.. (1998). Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. New England Journal of Medicine. 339(21). 1493–1499. 1070 indexed citations breakdown →
19.
Shiffman, Mitchell L., Charlotte M. Hofmann, Velimir A. Luketic, & Arun J. Sanyal. (1998). Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. Journal of Hepatology. 28(3). 382–389. 22 indexed citations
20.
Sanyal, Arun J., et al.. (1996). The hematologic consequences of transjugular intrahepatic portosystemic shunt. Hepatology. 23(1). 32–39. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Craxı̀ Breakdown of academic impact, for papers by Zachary Goodman Breakdown of academic impact, for papers by Thierry Poynard Breakdown of academic impact, for papers by Adrian M. Di Bisceglie Breakdown of academic impact, for papers by Eugene R. Schiff Breakdown of academic impact, for papers by John G. McHutchison Breakdown of academic impact, for papers by Patrick Marcellin Breakdown of academic impact, for papers by K. Rajender Reddy Breakdown of academic impact, for papers by Norah A. Terrault Breakdown of academic impact, for papers by Raymond T. Chung
Rankless by CCL
2026